J&J/Cordis and Guidant arbitration
This article was originally published in The Gray Sheet
Executive Summary
Ruling on Lau patent disputes, in which Guidant asserts infringement by Cordis' BX Velocity and Omni BX stents, is expected in early 2004. Guidant's Lau patent infringement claims against J&J/Cordis will be the second patent issue decided under the firms' April 2000 stent patent arbitration and cross-licensing deal. An Aug. 20 arbitration panel upheld a June decision to award J&J/Cordis $425 mil. for the infringement of its Palmaz-Schatz patents by Guidant's Multi-Link Duet coronary stent system (1The Gray Sheet" June 9, 2003, p. 22). Guidant set aside the money following the initial ruling and will incur no further costs due to the cross-licensing arrangement...
You may also be interested in...
Guidant To Seek Review Of $425 Mil. Patent Suit Arbitration Award To Cordis
Guidant stent sales will not be affected by a June 5 arbitration panel finding that the firm infringed Johnson &Johnson/Cordis' Palmaz-Schatz patents, Guidant says
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: